The FDA sent a letter to Eli Lilly scolding the drugmaker for Instagram ads it posted for its Type 2 diabetes drug Trulicity. In the letter, dated Jan. 19, the FDA said the ads do not adequately ...
FDA chides Eli Lilly for 2nd misleading ad in 2 months, this time for diabetes blockbuster Trulicity
After neatly wrapping up concerns over a series of Emgality ads last month, Eli Lilly is back in hot water with the FDA's Office of Prescription Drug Promotion. The FDA gave Lilly a slap on the wrist ...
Sanofi and Regeneron’s immunology blockbuster Dupixent was knocked down into second place as Eli Lilly’s diabetes medicine Trulicity took the top spot for January’s biggest TV ad spenders, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback